US2013071326A1PendingUtilityA1

Universal cell-directed theranostics

42
Individually held — no corporate assignee on recordPriority: Mar 17, 2010Filed: Mar 17, 2011Published: Mar 21, 2013
Est. expiryMar 17, 2030(~3.6 yrs left)· nominal 20-yr term from priority
Inventors:Jonathan O. MartinezEnnio TasciottiMikhail KoloninMauro Ferrari
A61P 35/00A61P 29/00A61K 9/5115A61K 9/1271A61K 9/5068A61P 17/02A61K 9/5176A61K 9/14A61K 49/00A61K 9/5123A61K 9/0019Y02A50/30
42
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides modified stem cells that comprise a delivery system that comprises at least one microparticle or nanoparticle, wherein the at least one microparticle or nanoparticle comprises an active agent. The present invention also provides delivery methods that comprise the administration of the modified stem cells to a subject. Additional aspects of the present invention pertain to methods of making said modified stem cells.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A modified stem cell comprising:
 a delivery system,
 wherein the delivery system comprises at least one microparticle or nanoparticle, and
 wherein the at least one microparticle or nanoparticle comprises an active agent. 
 
   
     
     
         2 . The modified stem cell of  claim 1 , wherein the at least one microparticle or nanoparticle comprises a porous particle. 
     
     
         3 . The modified stem cell of  claim 2 , wherein the porous particle comprises at least one of a nanoporous silicon particle or a nanoporous silica particle. 
     
     
         4 . The modified stem cell of  claim 1 , wherein the at least one microparticle or nanoparticle is selected from the group consisting of multistage particles, porous particles, porous silicon particles, porous silica particles, non-porous particles, fabricated particles, polymeric particles, synthetic particles, semiconducting particles, viruses, gold particles, silver particles, quantum dots, indium phosphate particles, iron oxide particles, micelles, liposomes, silica particles, mesoporous silica particles, PLGA-based particles, gelatin-based particles, carbon nanotubes, fullerenes, and combinations thereof. 
     
     
         5 . The modified stem cell of  claim 1 , wherein the at least one microparticle or nanoparticle comprises a particle with a functionalized surface. 
     
     
         6 . The modified stem cell of  claim 5 , wherein the surface of the particle is functionalized with a functionalizing agent selected from the group consisting of peptides, polymers, chitosans, contrasting agents, imaging agents and calcium phosphates. 
     
     
         7 . The modified stem cell of  claim 5 , wherein the surface of the particle is functionalized with a polymer, wherein the polymer becomes swellable in response to a stimulus selected from the group consisting of change in temperature, change in pH, change in pressure, and combinations thereof. 
     
     
         8 . The modified stem cell of  claim 1 , wherein the active agent comprises a therapeutic agent. 
     
     
         9 . The modified stem cell of  claim 8 , wherein the therapeutic agent is selected from the group consisting of anti-inflammatory agents, anti-cancer agents, anti-proliferative agents, anti-vascularization agents, wound repair agents, tissue repair agents, thermal therapy agents, and combinations thereof. 
     
     
         10 . The modified stem cell of  claim 1 , wherein the active agent comprises an imaging agent. 
     
     
         11 . The modified stem cell of  claim 1 , wherein the modified stem cell is selected from the group consisting of adult stem cells, embryonic stem cells, fetal stem cells, mesenchymal stem cells, neural stem cells, totipotent stem cells, pluripotent stem cells, multipotent stem cells, oligopotent stem cells, unipotent stem cells, adipose stromal cells, endothelial stem cells, and combinations thereof. 
     
     
         12 . The modified stem cell of  claim 1 , wherein the modified stem cell is an adipose stromal stem cell. 
     
     
         13 . The modified stem cell of  claim 1 , wherein the delivery system is a multistage delivery system. 
     
     
         14 . The modified stem cell of  claim 1 , wherein the delivery system is on a surface of the modified stem cell. 
     
     
         15 . The modified stem cell of  claim 1 , wherein the delivery system is inside the modified stem cell. 
     
     
         16 . The modified stem cell of  claim 1 , wherein the modified stem cell is used to treat, monitor, diagnose, or prevent a condition associated with inflammation. 
     
     
         17 . The modified stem cell of  claim 14 , wherein the condition to be treated, monitored, diagnosed, or prevented is cancer. 
     
     
         18 . A delivery method comprising:
 administering to a subject a modified stem cell comprising:
 a delivery system, wherein the delivery system comprises at least one microparticle or nanoparticle, and
 wherein the at least one microparticle or nanoparticle comprises an active agent. 
 
   
     
     
         19 . The delivery method of  claim 18 , wherein the administering comprises at least one of intravenous administration, subcutaneous administration, and intramuscular administration. 
     
     
         20 . The delivery method of  claim 18 , wherein the modified stem cell is selected from the group consisting of adult stem cells, embryonic stem cells, fetal stem cells, mesenchymal stem cells, neural stem cells, totipotent stem cells, pluripotent stem cells, multipotent stem cells, oligopotent stem cells, unipotent stem cells, adipose stromal cells, endothelial stem cells, and combinations thereof. 
     
     
         21 . The delivery method of  claim 18 , wherein the modified stem cell is derived directly from the subject. 
     
     
         22 . The delivery method of  claim 18 , wherein the subject is a human being suffering from a condition. 
     
     
         23 . The delivery method of  claim 22 , wherein the condition is associated with inflammation. 
     
     
         24 . The delivery method of  claim 23 , wherein the condition associated with inflammation is cancer. 
     
     
         25 . The delivery method of  claim 22 , wherein the modified stem cell migrates to a site associated with the condition within the subject after administration. 
     
     
         26 . The delivery method of  claim 25 , wherein the active agent is released from the modified stem cell after migration to the site associated with the condition. 
     
     
         27 . The delivery method of  claim 26 , wherein the release of the active agent from the modified stem cell comprises lysis of the modified stem cells. 
     
     
         28 . The delivery method of  claim 27 , further comprising inducing the lysis of the modified stem cells by exposing the stem cells to a stimulus selected from the group consisting of radiofrequency signals, heat, magnetic field radiation, light, changes in pressure, changes in pH, changes in temperature and combinations thereof. 
     
     
         29 . The delivery method of  claim 26 , wherein the release of the active agent from the modified stem cell comprises time-dependent necrosis of the modified stem cells. 
     
     
         30 . The delivery method of  claim 18 , wherein the active agent comprises a therapeutic agent selected from the group consisting of anti-inflammatory agents, anti-cancer agents, anti-proliferative agents, anti-vascularization agents, wound repair agents, tissue repair agents, thermal therapy agents, and combinations thereof. 
     
     
         31 . The delivery method of  claim 18 , wherein the active agent comprises an imaging agent. 
     
     
         32 . The delivery method of  claim 18 , wherein the at least one microparticle or nanoparticle is selected from the group consisting of multistage particles, porous particles, porous silicon particles, porous silica particles, non-porous particles, fabricated particles, polymeric particles, synthetic particles, semiconducting particles, viruses, gold particles, silver particles, quantum dots, indium phosphate particles, iron oxide particles, micelles, liposomes, silica particles, mesoporous silica particles, PLGA-based particles, gelatin-based particles, carbon nanotubes, fullerenes, and combinations thereof. 
     
     
         33 . The delivery method of  claim 18 , wherein the at least one microparticle or nanoparticle comprises a particle with a functionalized surface, wherein the surface is functionalized with a functionalizing agent selected from the group consisting of peptides, polymers, chitosans, contrasting agents, imaging agents and calcium phosphates. 
     
     
         34 . The delivery method of  claim 18 , wherein the delivery system is on a surface of the modified stem cell. 
     
     
         35 . The delivery method of  claim 18 , wherein the delivery system is inside the modified stem cell. 
     
     
         36 . A method of modifying a stem cell, wherein the method comprises:
 associating a delivery system with the stem cell, wherein the delivery system comprises at least one microparticle or nanoparticle, and
 wherein the at least one microparticle or nanoparticle comprises an active agent. 
   
     
     
         37 . The method of  claim 36 , wherein the associating comprises introducing the delivery system inside the stem cell. 
     
     
         38 . The method of  claim 36 , wherein the associating comprises conjugating the delivery system onto a surface of the stem cell. 
     
     
         39 . The method of  claim 38 , wherein the conjugating is facilitated by one or more functional groups on a surface of the delivery system. 
     
     
         40 . The method of  claim 36 , wherein the associating comprises incubating the delivery system with the stem cell. 
     
     
         41 . The method of  claim 36 , wherein the at least one microparticle or nanoparticle is selected from the group consisting of multistage particles, porous particles, porous silicon particles, porous silica particles, non-porous particles, fabricated particles, polymeric particles, synthetic particles, semiconducting particles, viruses, gold particles, silver particles, quantum dots, indium phosphate particles, iron oxide particles, micelles, liposomes, silica particles, mesoporous silica particles, PLGA-based particles, gelatin-based particles, carbon nanotubes, fullerenes. and combinations thereof. 
     
     
         42 . The method of  claim 36 , wherein the at least one microparticle or nanoparticle comprises a particle with a functionalized surface. 
     
     
         43 . The method of  claim 42 , wherein the surface of the particle is functionalized with a functionalizing agent selected from the group consisting of peptides, polymers, chitosans, contrasting agents, imaging agents and calcium phosphates. 
     
     
         44 . The method of  claim 42 , wherein the surface of the particle is functionalized with a polymer, wherein the polymer becomes swellable in response to a stimulus selected from the group consisting of change in temperature, change in pH, change in pressure, and combinations thereof. 
     
     
         45 . The method of  claim 36 , wherein the active agent comprises a therapeutic agent. 
     
     
         46 . The method of  claim 45 , wherein the therapeutic agent is selected from the group consisting of anti-inflammatory agents, anti-cancer agents, anti-proliferative agents, anti-vascularization agents, wound repair agents, tissue repair agents, thermal therapy agents, and combinations thereof. 
     
     
         47 . The method of  claim 36 , wherein the active agent comprises an imaging agent. 
     
     
         48 . The method of  claim 36 , wherein the stem cell is selected from the group consisting of adult stem cells, embryonic stem cells, fetal stem cells, mesenchymal stem cells, neural stem cells, totipotent stem cells, pluripotent stem cells, multipotent stem cells, oligopotent stem cells, unipotent stem cells, adipose stromal cells, endothelial stem cells, and combinations thereof. 
     
     
         49 . The method of  claim 36 , wherein the stem cell is an adipose stromal stem cell. 
     
     
         50 . The method of  claim 36 , wherein the delivery system is a multistage delivery system. 
     
     
         51 . The method of  claim 36 , wherein the modified stem cell is used to treat, monitor, diagnose, or prevent a condition associated with inflammation. 
     
     
         52 . The method of  claim 51 , wherein the condition to be treated, monitored, diagnosed, or prevented is cancer.

Join the waitlist — get patent alerts

Track US2013071326A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.